BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 11237496)

  • 1. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases.
    Petrowsky H; Sturm I; Graubitz O; Kooby DA; Staib-Sebler E; Gog C; Köhne CH; Hillebrand T; Daniel PT; Fong Y; Lorenz M
    Eur J Surg Oncol; 2001 Feb; 27(1):80-7. PubMed ID: 11237496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases].
    Aldrighetti L; Castoldi R; Di Palo S; Arru M; Stella M; Orsenigo E; Gavazzi F; Ferla G; Di Carlo V; Staudacher C
    Chir Ital; 2005; 57(5):555-70. PubMed ID: 16241086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of K-ras mutations with liver metastases from colorectal carcinoma.
    Tsunoda A; Iijima T; Tsunoda Y; Nakao K; Miyaki M; Kusano M
    Anticancer Res; 2004; 24(4):2471-6. PubMed ID: 15330200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors.
    De Jong KP; Stellema R; Karrenbeld A; Koudstaal J; Gouw AS; Sluiter WJ; Peeters PM; Slooff MJ; De Vries EG
    Hepatology; 1998 Oct; 28(4):971-9. PubMed ID: 9755233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic disseminated tumor cells in colorectal cancer UICC stage 4 patients: prognostic implications.
    Schimanski CC; Linnemann U; Galle PR; Arbogast R; Berger MR
    Int J Oncol; 2003 Sep; 23(3):791-6. PubMed ID: 12888919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence.
    Sanchez-Cespedes M; Esteller M; Hibi K; Cope FO; Westra WH; Piantadosi S; Herman JG; Jen J; Sidransky D
    Clin Cancer Res; 1999 Sep; 5(9):2450-4. PubMed ID: 10499618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
    Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
    Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality.
    Al-Mulla F; Going JJ; Sowden ET; Winter A; Pickford IR; Birnie GD
    J Pathol; 1998 Jun; 185(2):130-8. PubMed ID: 9713338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver.
    Schimanski CC; Linnemann U; Berger MR
    Cancer Res; 1999 Oct; 59(20):5169-75. PubMed ID: 10537293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer.
    Yamaguchi K; Chijiiwa K; Torato N; Kinoshita M; Tanaka M
    Am J Gastroenterol; 2000 Aug; 95(8):1939-45. PubMed ID: 10950039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of DCC and Ki-ras gene alterations in colorectal carcinoma tissue as prognostic markers for liver metastatic recurrence.
    Kato M; Ito Y; Kobayashi S; Isono K
    Cancer; 1996 Apr; 77(8 Suppl):1729-35. PubMed ID: 8608570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer.
    Gnanasampanthan G; Elsaleh H; McCaul K; Iacopetta B
    J Pathol; 2001 Dec; 195(5):543-8. PubMed ID: 11745689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. K-ras codon 12 and 13 mutations are correlated with differential patterns of tumor cell dissemination in colorectal cancer patients.
    Conzelmann M; Linnemann U; Berger MR
    Int J Oncol; 2004 Jun; 24(6):1537-44. PubMed ID: 15138598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
    de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
    Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of colorectal nonpolypoid adenomas: a prospective colonoscopic study and relation with cell kinetics and K-ras mutations.
    Watari J; Saitoh Y; Obara T; Fujiya M; Maemoto A; Ayabe T; Ashida T; Yokota K; Orii Y; Kohgo Y
    Am J Gastroenterol; 2002 Aug; 97(8):2109-15. PubMed ID: 12190185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection.
    Yang Y; Forslund A; Remotti H; Lönnroth C; Andersson M; Brevinge H; Svanberg E; Lindnér P; Hafström L; Naredi P; Lundholm K
    Cancer; 2001 Feb; 91(4):727-36. PubMed ID: 11241240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers.
    Lee JC; Wang ST; Lai MD; Lin YJ; Yang HB
    Anticancer Res; 1996; 16(6B):3839-44. PubMed ID: 9042267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of Ki-ras mutations and DNA alkylation in colorectal tissue from individuals living in Manchester.
    Jackson PE; Hall CN; Badawi AF; O'Connor PJ; Cooper DP; Povey AC
    Mol Carcinog; 1996 May; 16(1):12-9. PubMed ID: 8634090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.
    Etienne-Grimaldi MC; Formento JL; Francoual M; François E; Formento P; Renée N; Laurent-Puig P; Chazal M; Benchimol D; Delpero JR; Letoublon C; Pezet D; Seitz JF; Milano G
    Clin Cancer Res; 2008 Aug; 14(15):4830-5. PubMed ID: 18676755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.